Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan

OBJECTIVE: Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of ulcerative colitis (UC). The objective of this study was to evaluate the long-term cost-effectiveness of tofacitinib versus current biologics, considering combinations of first-line (1L) and second-line (2L) thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Taku, Hoshi, Masato, Yuasa, Akira, Arai, Shoko, Ikeda, Mitsunobu, Matsuda, Hiroyuki, Kim, Seok-Won, Hibi, Toshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085930/
https://www.ncbi.nlm.nih.gov/pubmed/36884164
http://dx.doi.org/10.1007/s40273-023-01254-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085930/
https://www.ncbi.nlm.nih.gov/pubmed/36884164
http://dx.doi.org/10.1007/s40273-023-01254-x

Ejemplares similares